The companies have agreed to offer their services together to parties such as pharmaceutical companies, who may be seeking a patient-friendly intranasal Phylomer peptide developed against their target of interest.
Paul Watt, Phylogica’s CSO and vice president of corporate development, said: “I am delighted at the agreement since the synergy between Phylomer peptides and the Intravail delivery platform was so compelling. Phylomer peptides are of an ideal size to deliver as a nasal spray using the Intravail formulation, since they are much smaller than proteins such as antibodies, which are delivered far less efficiently by means other than injection.”
Ed Maggio, CEO of Aegis, said: “Peptide therapeutics are among the most potent and safe drugs ever developed. Phylomer technology, for the first time, can harness the nearly unlimited structural diversity found in thousands of naturally occurring protein-folds to greatly expand the prospects of novel, safe and effective peptide therapeutics in virtually any disease category.”